MRNA241011C84000
- 0.05
- 0.000.00%
Moderna Newsroom
Covid-Shot Maker Goes Bankrupt After Trailing Pfizer, Moderna
Moderna Stock Touches 52-week Low at $57.71 Amid Market Shifts
Healthcare Stocks Are Showing Life Beyond Lilly and GLP-1s -- Barrons.com
Redburn Atlantic Adjusts Moderna's Price Target to $73 From $102, Keeps Neutral Rating
Moderna (MRNA) Stock Drops Despite Market Gains: Important Facts to Note
(MRNA) - Analyzing Moderna's Short Interest
Top-rated S&P 500 per SA Quant System as Q3 Earnings Near; Tech Remains a Top Pick
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
GSK Arexvy Protects From RSV Over Three Full Seasons
glaxosmithkline (GSK.US) claimed that the protection of the RSV vaccine can last for three quarters.
glaxosmithkline (GSK.US) stated on Tuesday that its respiratory syncytial virus (RSV) vaccine has protective effects in the three quarters after vaccination.
Express News | Reuters Reported Pfizer, Biontech Win Bid In UK Court To Invalidate Curevac's Patents Over MRNA Technology In Covid-19 Vaccines
Moderna Options Spot-On: On October 7th, 53,115 Contracts Were Traded, With 506.05K Open Interest
10 Health Care Stocks Whale Activity In Today's Session
Stocks on Sale, Novavax, Moderna, and More
Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?
Goldman Sachs Adjusts Price Target on Moderna to $130 From $139
Express News | Exclusive-Thermo Fisher's Greenville, North Carolina Plant Was Found in Breach of US FDA Regulations, Documents Show
Express News | Exclusive-FDA Says the Thermo Fisher Plant Addressed Concerns About Safety Issues Raised in the Audit
Express News | Exclusive-Sanofi Says FDA Findings Were Addressed, All Beyfortus Doses Were Approved by FDA Before They Were Shipped
Express News | Exclusive-FDA's Most Recent Inspection of Thermo Fisher Plant Found Shortfalls in Manufacturing of AstraZeneca's and Sanofi's Beyfortus Rsv Treatment